Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | ADA | P00813 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18934142 | 1.00 | FAAH (0.42) | FAAHCES1SLC2A1GPR84NR1I2 | |
| SCHEMBL20893257 | 1.00 | FAAH (0.42) | FAAHCES1SLC2A1GPR84NR1I2 | |
| SCHEMBL22692970 | 1.00 | FAAH (0.42) | FAAHCES1SLC2A1GPR84NR1I2 | |
| SCHEMBL20098073 | 0.98 | FAAH (0.41) | FAAHCES1SLC2A1GPR84NR1I2 | |
| SCHEMBL19852979 | 0.93 | FAAH (0.40) | FAAHCES1SLC2A1GPR84NR1I2 | |
| SCHEMBL27336909 | 0.93 | FAAH (0.38) | FAAHCES1LMNA | |
| SCHEMBL6922325 | 0.88 | FAAH (0.40) | FAAHCES1LMNA | |
| SCHEMBL26646458 | 0.86 | FAAH (0.36) | FAAHCES1NR1I2LMNA | |
| SCHEMBL20612594 | 0.85 | FAAH (0.33) | FAAHCES1 | |
| SCHEMBL24221550 | 0.78 | FAAH (0.32) | FAAHCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | FAAH 3480/4885CES1 2884/4885SLC2A1 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.